BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125 SEK | -2.95% | +6.02% | +23.52% |
05-07 | Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders | DJ |
05-07 | Transcript : BioGaia AB, Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.52% | 1.16B | |
-3.32% | 88.91B | |
+2.76% | 41.25B | |
-13.92% | 31.99B | |
+50.51% | 24.73B | |
-15.25% | 15.54B | |
-39.93% | 12.07B | |
-9.08% | 12.05B | |
-14.80% | 12.02B | |
+6.22% | 8.84B |
- Stock Market
- Equities
- BIOG B Stock
- News BioGaia AB
- Biogaia AB Appoints Theresa Agnew as CEO